NewAmsterdam Pharma Company N.V.

As of June 30, 2026, NewAmsterdam Pharma Company N.V. carries a market capitalization of 3.50B, placing it among publicly traded companies globally. Its enterprise value stands at 2.94B, reflecting the total theoretical takeover cost after accounting for cash holdings and debt obligations.

NewAmsterdam Pharma Company N.V.'s next confirmed earnings release is scheduled for November 11, 2026.

As of June 30, 2026, NewAmsterdam Pharma Company N.V. has 117.65M shares outstanding.

These figures are as of June 30, 2026. The price-to-sales ratio is 563.37, and the price-to-book ratio stands at 6.32.

These figures are as of June 30, 2026. The EV/Sales ratio of 471.79 reflects the premium investors pay for the company's revenue stream, a useful check when earnings are depressed or negative. These enterprise value multiples are built on an enterprise value of 2.94B versus a market cap of 3.50B, with the gap driven by net debt and cash on the balance sheet.

As of June 30, 2026, NewAmsterdam Pharma Company N.V. maintains a current ratio of 9.03, meaning it holds 9.0x the short-term assets needed to cover near-term liabilities.

Over the twelve months ended June 30, 2026, NewAmsterdam Pharma Company N.V. posted a negative return on equity (ROE) of -36.81, meaning shareholder capital produced losses rather than profits. Return on assets (ROA) is negative at -34.16, reflecting losses generated across the asset base. The company generates approximately 67,750.12 in revenue per employee across its workforce of 92.00, a quick read on workforce productivity versus industry peers.

As of the close on October 22, 2026, NewAmsterdam Pharma Company N.V.'s stock has declined approximately 35.93% over the past 52 weeks. The 50-day moving average sits at 20.63, while the 200-day moving average is 26.00.

Over the twelve months ended June 30, 2026, NewAmsterdam Pharma Company N.V. generated 6.23M in revenue and converted that into -227.14M in net income, yielding earnings per share of -1.92. EBITDA reached -213.72M, while operating income came in at -213.93M.

As of June 30, 2026, NewAmsterdam Pharma Company N.V. holds 554.81M in cash and equivalents against 71,774.60 in total debt, resulting in a net debt position of -371.26M. Total book value stands at 552.68M, with working capital of 513.13M providing operational flexibility.

NewAmsterdam Pharma Company N.V. produced -125.57M in operating cash flow over the twelve months ended June 30, 2026. After subtracting -227,578.00 in capital expenditures, free cash flow totaled -125.80M - equivalent to -1.06 per share.

These figures cover the twelve months ended June 30, 2026. The operating margin of -3,432.20 and net profit margin of -3,644.21 provide insight into operational efficiency.

These figures cover the twelve months ended June 30, 2026. Free cash flow yield is negative at -3.58: the business is consuming cash rather than generating it, so any dividend is not covered by free cash flow. Total shareholder yield is negative at -1.04, meaning NewAmsterdam Pharma Company N.V. raised more capital through share issuance and new debt than it returned via dividends and buybacks.

As of June 30, 2026, NewAmsterdam Pharma Company N.V. has an Altman Z-Score of 30.93, well above the 3.0 threshold that indicates strong financial health and minimal bankruptcy risk.